Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNotes PayablesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CNBX Pharmaceuticals (CNBX) Total Current Liabilities (2016 - 2025)

CNBX Pharmaceuticals (CNBX) has disclosed Total Current Liabilities for 14 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 1.87% year-over-year to $2.6 million, compared with a TTM value of $2.6 million through Nov 2025, up 1.87%, and an annual FY2025 reading of $2.5 million, changed 0.13% over the prior year.
  • Total Current Liabilities was $2.6 million for Q4 2025 at CNBX Pharmaceuticals, up from $2.5 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $2.6 million in Q1 2025 and bottomed at $1.2 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $2.2 million, with a median of $2.5 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities skyrocketed 241.75% in 2021, then dropped 3.93% in 2023.
  • Year by year, Total Current Liabilities stood at $1.5 million in 2021, then soared by 73.09% to $2.6 million in 2022, then decreased by 3.93% to $2.5 million in 2023, then rose by 2.19% to $2.5 million in 2024, then grew by 1.87% to $2.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for CNBX at $2.6 million in Q4 2025, $2.5 million in Q3 2025, and $2.6 million in Q2 2025.